
NRx Pharmaceuticals and Nephron Pharmaceuticals Announce Joint Agreement to Develop Intravenous Ketamine to Treat Suicidal Depression
RADNOR, PA — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) and Nephron Pharmaceuticals, Inc. announced the recent signing of a development and manufacturing agreement to manufacture a presentation of ketamine suitable for …
NRx Pharmaceuticals and Nephron Pharmaceuticals Announce Joint Agreement to Develop Intravenous Ketamine to Treat Suicidal Depression Read More